Davita Inc vs WisdomTree Inc. Common Stock — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while WisdomTree Inc. Common Stock trades at $22.83 (market cap $3.54B). The key difference: Davita Inc is far larger — about 3.2× WisdomTree Inc. Common Stock's market cap, and WisdomTree Inc. Common Stock pays a 0.51% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and WisdomTree Inc. Common Stock for 0 Days on average.
| DVA | WT | |
|---|---|---|
Market Cap | $11.28B | $3.54B |
Volume | 650,294 | 1,948,608 |
Sector | Health | Financials |
52-Week High | $240.96 | $25.04 |
52-Week Low | $103.87 | $10.73 |
Typical Hold Time | 113 Days | 0 Days |
Enterprise Value | $24.00B | $4.29B |
Dividend Yield | — | 0.51% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →WisdomTree provides exchange-traded products, model portfolios, and digital-asset-related products and services. Its digital offerings include tokenized funds, an institutional platform, and a blockchain-native wallet.
Read more on WT →